Journal Article

Risk Factors for Development of Tuberculosis after Isoniazid Chemoprophylaxis in Human Immunodeficiency Virus—Infected Patients

José L. Casado, Santiago Moreno, Jesús Fortún, Antonio Antela, Carmen Quereda, Enrique Navas, Ana Moreno and Fernando Dronda

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 34, issue 3, pages 386-389
Published in print February 2002 | ISSN: 1058-4838
Published online February 2002 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/324746
Risk Factors for Development of Tuberculosis after Isoniazid Chemoprophylaxis in Human Immunodeficiency Virus—Infected Patients

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

The long-term benefit of isoniazid chemoprophylaxis in human immunodeficiency virus (HIV)–infected patients and risk factors for isoniazid failure were studied in 131 HIV-infected patients who received >9 months of isoniazid preventive therapy. During a median follow-up of 43 months, 8 patients developed tuberculosis (TB) (6%; 0.61 cases per 100 patient-years). Only the persistence of risk factors for exposure to TB was statistically associated with development of disease (relative hazard, 3.17; 95% confidence interval, 1.56–17; P < .001). Our data suggest reinfection as the main cause of TB after isoniazid prophylaxis.

Journal Article.  2546 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.